Literature DB >> 15813716

Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions.

Jeffrey K Aronson1.   

Abstract

Anecdotal case reports contribute about one-third of the published literature on adverse drug reactions and interactions, but are regarded as providing poor-quality evidence. However, they can occasionally provide proof of cause and effect, and there are many other reasons for publishing them. Because an anecdote is a narrative, narratological paradigms from literature, art, and music can show how we can make evidential use of anecdotes. Useful paradigms are the dramatic unities (of time, place, and action), comprehensive catalogues, and pattern formations. Here I give examples of each of these types of paradigm and show how they can be used to interpret anecdotes about adverse drug reactions and interactions. The dramatic unities show how a proper classification of adverse drug reactions can be achieved, according to dose-relation, time-course, and susceptibility factors; use of this classification should improve the evidential use of anecdotal reports. A high background incidence of the effect (the medical equivalent of subplots, which violate the unity of action) makes it more difficult to detect adverse drug effects using anecdotal reports. To make best evidential use of the corpus of anecdotal reports of adverse drug reactions, comprehensiveness is important: each suspected adverse reaction should be reported in detail and reactions should be reported in sufficient numbers for proper classification and for patterns to be recognized. One form of pattern recognition, teleoanalysis of data, should, when possible, include not only randomized controlled trials and observational studies, but also case series and anecdotal reports.

Mesh:

Year:  2005        PMID: 15813716     DOI: 10.1111/j.1365-2753.2005.00527.x

Source DB:  PubMed          Journal:  J Eval Clin Pract        ISSN: 1356-1294            Impact factor:   2.431


  10 in total

1.  What Is the Plural of a 'Yellow' Anecdote?

Authors:  Stephen J W Evans
Journal:  Drug Saf       Date:  2016-01       Impact factor: 5.606

2.  Metameta-analysis.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2005-08       Impact factor: 4.335

3.  Prescribing statins.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2005-11       Impact factor: 4.335

4.  An agenda for research on adverse drug reactions.

Authors:  J K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-08       Impact factor: 4.335

5.  Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

6.  The evolution of evidence hierarchies: what can Bradford Hill's 'guidelines for causation' contribute?

Authors:  Jeremy Howick; Paul Glasziou; Jeffrey K Aronson
Journal:  J R Soc Med       Date:  2009-05       Impact factor: 5.344

7.  Outliers and patients with adverse drug reactions.

Authors:  I Ralph Edwards
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  WITHDRAWN: Diclofenac for acute pain in children.

Authors:  Joseph F Standing; Imogen Savage; Deborah Pritchard; Marina Waddington
Journal:  Cochrane Database Syst Rev       Date:  2015-07-02

9.  Pharmacovigilance on the turn? Adverse reactions methods in 2012.

Authors:  Andrew Herxheimer
Journal:  Br J Gen Pract       Date:  2012-08       Impact factor: 5.386

Review 10.  Dietary supplements, herbs and oral anticoagulants: the nature of the evidence.

Authors:  Ann K Wittkowsky
Journal:  J Thromb Thrombolysis       Date:  2007-09-29       Impact factor: 2.300

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.